Get the Stockscreener App
328.20
0.15%
-0.49
After Hours:
328.20
Penumbra Inc stock is traded at $328.20, with a volume of 315.23K.
It is down -0.15% in the last 24 hours and down -0.51% over the past month.
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.
See More
Previous Close:
$328.69
Open:
$328.12
24h Volume:
315.23K
Relative Volume:
0.57
Market Cap:
$12.91B
Revenue:
$1.40B
Net Income/Loss:
$177.69M
P/E Ratio:
72.56
EPS:
4.5234
Net Cash Flow:
$174.93M
1W Performance:
+0.51%
1M Performance:
-0.51%
6M Performance:
+10.89%
1Y Performance:
+22.22%
1-Day Range:
$327.81
$329.65
1-Week Range:
$325.13
$329.67
52-Week Range:
$221.26
$362.41
Penumbra Inc Stock (PEN) Company Profile
Name
Penumbra Inc
Sector
Industry
Phone
(510) 995-2486
Address
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
328.20 | 12.93B | 1.40B | 177.69M | 174.93M | 4.5234 |
ABT
Abbott Laboratories
|
86.67 | 152.25B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
313.00 | 121.33B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
77.60 | 100.91B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.64 | 85.88B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.54 | 49.39B | 6.30B | 1.07B | 1.09B | 1.8406 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-25 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-25 | Initiated | Wells Fargo | Underweight |
| Oct-08-25 | Upgrade | Needham | Hold → Buy |
| Sep-02-25 | Initiated | Evercore ISI | Outperform |
| Mar-14-25 | Initiated | BofA Securities | Buy |
| Jan-21-25 | Initiated | UBS | Buy |
| Dec-17-24 | Initiated | Oppenheimer | Outperform |
| Dec-11-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-18-24 | Initiated | Stifel | Buy |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-31-24 | Downgrade | Citigroup | Buy → Neutral |
| Jul-31-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-23-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-06-23 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Mar-29-23 | Downgrade | Needham | Buy → Hold |
| Jan-30-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Oct-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Sep-09-22 | Upgrade | Needham | Hold → Buy |
| Jul-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Apr-19-22 | Initiated | Deutsche Bank | Buy |
| Mar-08-22 | Initiated | Needham | Hold |
| Sep-16-21 | Initiated | Truist | Buy |
| Jun-04-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-07-20 | Resumed | Canaccord Genuity | Buy |
| Sep-29-20 | Initiated | BTIG Research | Buy |
| Sep-08-20 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| May-30-19 | Upgrade | JP Morgan | Neutral → Overweight |
| May-21-19 | Initiated | William Blair | Outperform |
| Oct-29-18 | Resumed | BofA/Merrill | Buy |
| Oct-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Feb-21-18 | Initiated | William Blair | Outperform |
| Jan-02-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-30-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-13-15 | Initiated | Wells Fargo | Outperform |
View All
Penumbra Inc Stock (PEN) Latest News
Penumbra, Inc. (PEN) Stock Analysis: A Healthcare Giant With A 10.55% Upside Potential - DirectorsTalk Interviews
Water Island Event-Driven Fund's Penumbra Inc(PEN) Holding History - GuruFocus
Penumbra stock hits 52-week high at $328.69 By Investing.com - Investing.com Australia
Penumbra stock hits 52-week high at $328.69 - Investing.com
Penumbra (PEN) CEO-linked trust donates 77,000 shares in charitable stock gift - Stock Titan
Peripheral Embolization Coils Market is experiencing boost - openPR.com
PEN Stock Price, Quote & Chart | PENUMBRA INC (NYSE:PEN) - ChartMill
(PEN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
ServisFirst Gets Axed by Champlain — a Minor Position in a Major Drawdown - The Motley Fool
HBK INVESTMENTS L P's Penumbra Inc(PEN) Holding History - GuruFocus
120,815 Shares in Penumbra, Inc. $PEN Purchased by Stephens Investment Management Group LLC - MarketBeat
Thrivent Financial for Lutherans Sells 72,330 Shares of Penumbra, Inc. $PEN - MarketBeat
Penumbra, Inc. (NYSE:PEN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Penumbra, Inc. (PEN) Stock Analysis: Navigating a 12.76% Upside in the Medical Devices Sector - DirectorsTalk Interviews
Penumbra, Inc. Reports Third Quarter 2025 Financial Results - Quantisnow
Penumbra Shareholders Approve Merger with Boston Scientific - The Globe and Mail
Penumbra revenue up 15.6% to USD 374.8M in Q1 2026 - Medical Buyer
PEN Maintained by Citigroup -- Price Target Lowered to $350 - GuruFocus
Citi Maintains Penumbra(PEN.US) With Hold Rating, Cuts Target Price to $350 - Moomoo
Penumbra Is Maintained at Outperform by Evercore ISI Group - Moomoo
Liquidity Mapping Around (PEN) Price Events - Stock Traders Daily
PEN Maintained by Evercore ISI Group -- Price Target Lowered to $335 - GuruFocus
Penumbra Is a 'Strong' Strategic Fit for Boston Scientific, RBC Says - Moomoo
Penumbra shareholders approve merger with Boston Scientific By Investing.com - Investing.com Australia
Penumbra, Inc. Q1 2026 Financial Results: Earnings, Comprehensive Income, and Stockholders’ Equity Highlights - Minichart
Penumbra IncStockholders approve merger with Boston ScientificSEC filing - marketscreener.com
Penumbra shareholders approve merger with Boston Scientific - Investing.com
Penumbra (NYSE: PEN) shareholders approve Merger Proposal; closing conditions remain - Stock Titan
Penumbra (NYSE: PEN) investors back merger, await antitrust approvals - Stock Titan
Evercore Maintains Penumbra(PEN.US) With Buy Rating, Cuts Target Price to $335 - Moomoo
Penumbra: Q1 Earnings Snapshot - theheraldreview.com
Assessing Penumbra (PEN) Valuation As Growth Expectations Meet A Premium P/E Multiple - Yahoo Finance
Penumbra Shareholder Notice - TMX Newsfile
MSN Money - MSN
Penumbra (PEN) Misses Q1 Earnings Estimates - Yahoo Finance
[10-Q] Penumbra Inc Quarterly Earnings Report - Stock Titan
Earnings Flash (PEN) Penumbra, Inc. Reports Q1 Revenue $374.8M, vs. FactSet Est of $371.3M - marketscreener.com
Penumbra (NYSE: PEN) posts $374.8M Q1 2026 revenue as Boston Scientific deal looms - Stock Titan
Penumbra posts $32.6M profit as Boston Scientific deal halts outlook - Stock Titan
Penumbra, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
PEN Technical Analysis | Trend, Signals & Chart Patterns | PENUMBRA INC (NYSE:PEN) - ChartMill
Penumbra earnings in focus as Boston Scientific deal looms By Investing.com - Investing.com South Africa
Penumbra earnings in focus as Boston Scientific deal looms - Investing.com
Penumbra, Inc. (PEN) Stock Analysis: A 12.44% Potential Upside in the Thriving Medical Devices Sector - DirectorsTalk Interviews
Vanguard Group Inc. Cuts Stock Position in Penumbra, Inc. $PEN - MarketBeat
Inside Boston Scientific's $15 billion offer for Alameda's largest employer - The Business Journals
Penumbra Inc Stock (PEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
2.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):